As early as 2011, a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) called ipilimumab was already approved for metastasized melanoma to recover appropriate cytotoxicity from T cells to kill cancer cells [23, 24]. The gene discussed is CTLA4; the disease is cancer.